Balyasny Asset Management Has Upped Q2 Holdings (QTWO) Holding by $2.38 Million as Market Valuation Rose; Rock Springs Capital Management LP Has Lowered Position in Paratek Pharmaceuticals (PRTK) as Shares Rose

February 12, 2018 - By Ellis Scott

Rock Springs Capital Management Lp decreased its stake in Paratek Pharmaceuticals Inc (PRTK) by 25% based on its latest 2017Q3 regulatory filing with the SEC. Rock Springs Capital Management Lp sold 150,000 shares as the company’s stock rose 33.85% with the market. The hedge fund held 450,000 shares of the health care company at the end of 2017Q3, valued at $11.30M, down from 600,000 at the end of the previous reported quarter. Rock Springs Capital Management Lp who had been investing in Paratek Pharmaceuticals Inc for a number of months, seems to be less bullish one the $428.36M market cap company. The stock increased 8.89% or $1.125 during the last trading session, reaching $13.775. About 476,678 shares traded or 2.05% up from the average. Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) has risen 62.03% since February 12, 2017 and is uptrending. It has outperformed by 45.33% the S&P500.

Dmitry Balyasny increased its stake in Q2 Holdings Inc (QTWO) by 52.51% based on its latest 2017Q3 regulatory filing with the SEC. Balyasny Asset Management Llc bought 58,124 shares as the company’s stock rose 8.75% with the market. The hedge fund run by Dmitry Balyasny held 168,806 shares of the technology company at the end of 2017Q3, valued at $7.03 million, up from 110,682 at the end of the previous reported quarter. Balyasny Asset Management Llc who had been investing in Q2 Holdings Inc for a number of months, seems to be bullish on the $1.77B market cap company. The stock increased 1.56% or $0.65 during the last trading session, reaching $42.45. About 100,664 shares traded. Q2 Holdings, Inc. (NYSE:QTWO) has risen 76.19% since February 12, 2017 and is uptrending. It has outperformed by 59.49% the S&P500.

Among 10 analysts covering Paratek Pharmaceuticals (NASDAQ:PRTK), 9 have Buy rating, 0 Sell and 1 Hold. Therefore 90% are positive. Paratek Pharmaceuticals had 24 analyst reports since July 23, 2015 according to SRatingsIntel. Leerink Swann maintained the shares of PRTK in report on Thursday, June 15 with “Buy” rating. The rating was initiated by Robert W. Baird with “Outperform” on Friday, May 13. The rating was upgraded by Zacks to “Hold” on Wednesday, September 2. Cantor Fitzgerald maintained the stock with “Buy” rating in Wednesday, August 23 report. The rating was maintained by Ladenburg Thalmann on Friday, June 17 with “Buy”. The rating was upgraded by Zacks on Friday, August 14 to “Sell”. The stock has “Buy” rating by H.C. Wainwright on Tuesday, July 18. On Monday, June 5 the stock rating was maintained by Cantor Fitzgerald with “Buy”. On Tuesday, September 22 the stock rating was upgraded by Zacks to “Hold”. Leerink Swann reinitiated the stock with “Outperform” rating in Thursday, October 27 report.

Rock Springs Capital Management Lp, which manages about $319.00 million and $2.17 billion US Long portfolio, upped its stake in Pra Health Sciences Inc by 15,000 shares to 477,500 shares, valued at $36.37M in 2017Q3, according to the filing. It also increased its holding in Bluebird Bio Inc (NASDAQ:BLUE) by 3,000 shares in the quarter, for a total of 35,000 shares, and has risen its stake in Willis Towers Watson Pub Ltd.

Analysts await Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) to report earnings on March, 1. They expect $-0.72 EPS, up 37.93% or $0.44 from last year’s $-1.16 per share. After $-0.77 actual EPS reported by Paratek Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -6.49% EPS growth.

Investors sentiment decreased to 1.54 in 2017 Q3. Its down 0.35, from 1.89 in 2017Q2. It is negative, as 17 investors sold PRTK shares while 29 reduced holdings. 33 funds opened positions while 38 raised stakes. 20.11 million shares or 4.43% more from 19.26 million shares in 2017Q2 were reported. Highland Cap Management Ltd Partnership holds 48,100 shares or 0.05% of its portfolio. Ameritas Inv Prns stated it has 0% in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). Laurion LP invested in 10,100 shares or 0% of the stock. California-based Schwab Charles Inv Management has invested 0% in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). Fortress Inv Gp Llc owns 433,804 shares or 0.24% of their US portfolio. Stoneridge Prtnrs Limited Liability Corporation invested in 0.05% or 11,634 shares. Moreover, Raymond James Finance Svcs Incorporated has 0% invested in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). Perceptive Advsrs Ltd Liability Com owns 0.02% invested in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) for 21,186 shares. Essex Invest Management Ltd Liability Corporation has invested 0.21% in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). Grp One Trading LP stated it has 28,432 shares. Invesco has invested 0% in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). 35,000 were reported by Iguana Mgmt Limited Company. Blackrock Inc reported 0% of its portfolio in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). Water Island Capital Ltd Llc has invested 0.11% of its portfolio in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). Millennium Llc stated it has 0.01% in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK).

Investors sentiment decreased to 1.45 in Q3 2017. Its down 0.16, from 1.61 in 2017Q2. It worsened, as 8 investors sold QTWO shares while 41 reduced holdings. 26 funds opened positions while 45 raised stakes. 33.93 million shares or 0.34% less from 34.05 million shares in 2017Q2 were reported. Cubist Systematic Strategies Ltd holds 6,680 shares. Stephens Inv Mgmt Grp Ltd Liability Corporation reported 856,395 shares. Riverhead Capital Management Lc invested in 16,500 shares. Baring Asset Limited stated it has 12,448 shares. Citigroup accumulated 0% or 830 shares. Swiss National Bank has invested 0% in Q2 Holdings, Inc. (NYSE:QTWO). California Pub Employees Retirement System reported 8,800 shares. Moreover, Art Advisors Limited Company has 0.02% invested in Q2 Holdings, Inc. (NYSE:QTWO). Los Angeles Capital Management Equity Rech Inc reported 0% of its portfolio in Q2 Holdings, Inc. (NYSE:QTWO). Australia-based Macquarie Gru Limited has invested 0.05% in Q2 Holdings, Inc. (NYSE:QTWO). Tiverton Asset Mgmt Ltd Liability Com holds 36,073 shares or 0.09% of its portfolio. Glenmede Tru Na owns 80 shares for 0% of their portfolio. Moreover, Rhumbline Advisers has 0% invested in Q2 Holdings, Inc. (NYSE:QTWO). Balyasny Asset Ltd Liability owns 0.03% invested in Q2 Holdings, Inc. (NYSE:QTWO) for 168,806 shares. Metropolitan Life Ins Co has 0.01% invested in Q2 Holdings, Inc. (NYSE:QTWO).

Since August 14, 2017, it had 0 buys, and 18 selling transactions for $11.09 million activity. Another trade for 20,000 shares valued at $737,200 was made by Schaper Carl James on Friday, December 29. $57,285 worth of Q2 Holdings, Inc. (NYSE:QTWO) shares were sold by Benton Barry G. On Friday, September 1 Flake Matthew P sold $1.19 million worth of Q2 Holdings, Inc. (NYSE:QTWO) or 30,000 shares. Breeden John E had sold 10,000 shares worth $394,200. Wittenburg Odus Edward Jr had sold 21,250 shares worth $847,663. Another trade for 26 shares valued at $1,074 was sold by DOYLE CHARLES T.

Among 16 analysts covering Q2 Holdings Inc (NYSE:QTWO), 10 have Buy rating, 0 Sell and 6 Hold. Therefore 63% are positive. Q2 Holdings Inc had 31 analyst reports since August 4, 2015 according to SRatingsIntel. The company was initiated on Tuesday, January 10 by Loop Capital. On Friday, November 3 the stock rating was maintained by Morgan Stanley with “Equal-Weight”. The company was downgraded on Thursday, November 2 by Canaccord Genuity. The firm has “Buy” rating by RBC Capital Markets given on Friday, November 3. As per Friday, February 17, the company rating was maintained by Needham. As per Friday, August 7, the company rating was maintained by RBC Capital Markets. The stock has “Hold” rating by KeyBanc Capital Markets on Monday, September 11. Canaccord Genuity maintained Q2 Holdings, Inc. (NYSE:QTWO) rating on Monday, June 5. Canaccord Genuity has “Buy” rating and $4300 target. The firm has “Buy” rating by Loop Capital given on Friday, November 3. As per Tuesday, June 21, the company rating was reinitiated by Needham.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>